Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and olanzapine

levofloxacin has been researched along with olanzapine in 12 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(olanzapine)		Trials
(olanzapine)		Recent Studies (post-2010) (olanzapine)
4,3465812,2096,3391,3402,383

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)olanzapine (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.097
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.155
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.047
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.04
Alpha-2A adrenergic receptorHomo sapiens (human)0.541
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)2.768
D(2) dopamine receptorHomo sapiens (human)0.118
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.047
Alpha-2B adrenergic receptorHomo sapiens (human)0.421
Alpha-2C adrenergic receptorHomo sapiens (human)0.531
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.392
D(1A) dopamine receptorHomo sapiens (human)0.072
D(4) dopamine receptorHomo sapiens (human)0.173
Alpha-1D adrenergic receptorHomo sapiens (human)0.092
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.038
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.021
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.047
Sodium-dependent serotonin transporterHomo sapiens (human)1.033
Histamine H1 receptorHomo sapiens (human)0.013
D(3) dopamine receptorHomo sapiens (human)0.078
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.057
5-hydroxytryptamine receptor 6Homo sapiens (human)0.013
D(2) dopamine receptorRattus norvegicus (Norway rat)0.158
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.2028

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (41.67)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keserü, GM1
Nagashima, R; Nishikawa, T; Tobita, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Jia, L; Sun, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for levofloxacin and olanzapine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

11 other study(ies) available for levofloxacin and olanzapine

ArticleYear
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014